The effects of glucose and oxygen on cultures at the stationary phase were also studied. Table 1 summarizes the results. As also reported by Manners & Ryley (1952) , Tetruhymenu can store large quantities of glycogen that serve as an energy source in anaerobic cells. The glycogenic capacity is lower in cells from shaken cultures, whereas cells from glucose-containing cultures cannot convert acetate into glycogen (Hogg & Kornberg, 1963; Levy & Hunt, 1967) . When cells that had been grown in glucose-free medium until the stationary phase were transferred to a glucose-supplemented medium, they showed increasing amounts of glycogen synthesis during the incubation time of 180niin. The amounts in static cultures were always higher than in shaken cultures. No remarkable changes in the activities of synthase or phosphorylase could be observed during synthesis of glycogen after addition of glucose. Also in these experiments the total and a forms of the glycogen-metabolizing enzymes did not show differences.
From these studies it is clear that glycogen synthase a and phosphorylase a activities are independent of glucose concentration or incubation conditions. Furthermore there was no relationship between the amounts of glycogen deposited and the synthase activity in the u form at the stationary phase. It may be that the glycogen synthesis in Tetruhymenu pyriforrnis is regulated by intracellular metabolites. A role for peroxisomes in the regulation of glycolysis in this protozoan has also been suggested (de Duve & Baudhuin, 1966) . Further investigation to clarify the mechanism of control involved in glycogen metabolism in these organisms is needed. terminal sialic acid and galactose residues (Patt & Grimes, 1974) . GDP-fucose-galactoside fucosyltransferase (F1 enzyme) activity was measured with GDP-['4C]fucose and a desialylated fetuin acceptor and GDP-fucose-N-acetylglucosaminide fucosyltransferase (F2 enzyme) activity with GDP-[14C]fucose and the fetuin acceptor lacking terminal sialic acid and galactose residues. The assay method for the latter two enzymes has been described , and utilizes the preferential inhibition of the F1 enzyme by N-ethylmaleimide to correct for endogenous activities of the two enzymes in plasma samples. We found essentially no elevation in F2 enzyme activity, and a slight (to 120-150% of control) elevation in sialyl-and galactosyl-transferase activity in plasma of patients with untreated acute leukaemias as compared with a control population. A marked increase in the plasma activity of the F1 enzyme (to 300% of control) was found in the untreated leukaemia group. In patients with progressive non-responding disease, still higher enzyme activities were found (Table 1) . We report a correlation between percentage of marrow myeloblasts and plasma F1 enzyme activity in another study (Khilanani et al., 1977) .
Although the plasma F2 enzyme activity was not elevated above control in untreated or non-responding patients, it increased substantially during drug-induced remissions. In such individuals, plasma enzyme activities of 300% of control were commonly encountered (Table l) , with transient values reaching 750% of control.
In six patients with acute myelogenous leukaemia, serial plasma samples could be obtained during a chemotherapeutic programme. A marked decrease in plasma F1 enzyme activity, associated with drug-induced remissions, was always accompanied by a corresponding increase in the plasma F2 enzyme activity.
We interpret these data as indicating that marrow status is reflected by the plasma activity of the two fucosyltransferases. F1 enzyme activity apparently provides an index of percentage of marrow blast cells, and that of F2 enzyme is associated with the appearance of normal regenerating cell types in marrow after drug-induced remissions. All of the patients studied here were maintained on a drug-therapy programme during remissions, with resulting myelosuppression. As a result, we have no data on plasma F2 enzyme activity during unmaintained remissions. We did, however, follow several patients with non-Hodgkin's lymphomas and noted an initial rise in plasma F2 enzyme activity within 3 weeks after a course of drug therapy. This fell to a control value during the weeks after therapy was ceased (Khilanani et al., 1978) .
An increase in the concentration of plasma protein-bound fucose has been observed in cancer patients (Evans et al., 1974; Lambana, 1976) . In a study using the analytical method of Evans et al. (1974) , we found a marked increase in protein-bound fucose (30&400% of control) in patients with increased plasma F1 enzyme activity, but no such result was found when the plasma F2 enzyme activity was elevated during drug-induced remissions (Table 1) . Apparently the appropriate acceptors for activity of the the former, but not of the latter, enzyme are found in these plasmas.
Kuhns et al. (1976) reported a decrease in F1 enzyme activity in plasma of patients with leukaemia; the enzyme activity rose to control values during remissions. This study was carried out with a low-molecular-weight fucose acceptor (Chester et al., 1976) . We have repeated this assay method with our leukaemic-patient plasma collection, with a similar result. This contradiction might be explained by competition for GDP-fucose between low-and high-molecular-weight endogenous acceptors. Alternatively, the two methods may measure different enzyme activities.
The presence of high concentrations of endogenous acceptor for both fucosyltransferases has complicated the assay procedure. We can discriminate against endogenous F1 enzyme activity in the F2 enzyme assay by carrying out the procedure in the presence of 10mM-N-ethylmaleirnide, which inhibits the former, but not the latter enzyme. The presence of endogenous F2 enzyme in the F1 enzyme assay is corrected for by carrying out a duplicate assay in the presence of the inhibitor, with the net enzyme activity calculated by subtraction . But competition between acceptors undoubtedly Vol. 6 leads to errors in the procedure. We have explored the use of immobilized 8-galactosidase and 8-acetylglucosaminidase columns to remove such acceptor activity from plasma before assays are carried out. Bauer et al. (1 977) found elevated activities of both fucosyltransferases in plasma obtained from cancer patients; the method does not permit correction for endogenous enzyme activity, and the report of elevated F2 enzyme activity in plasma of such patients might therefore reflect transfer of fucose to endogenous acceptors.
A study of fucosyltransferase activity in marrow cells obtained from patients with 90-100% marrow blast cells, and those in remission, revealed approximately equal activities of both fucosyltransferases in these marrow samples, although the total fucosyltransferase activity was 4-fold higher in leukaemic than in remission marrows ( Table 1 ). These data indicate that the preferential elevation of specific fucosyltransferases during different stages of acute leukaemia must involve preferential release of individual enzymes, either by marrow cells or from some other host site.
